Clinical Trials List
2025-01-01 - 2031-12-31
Phase III
Recruiting12
ICD-10G30.0
Alzheimer's disease with early onset
ICD-10G30.1
Alzheimer's disease with late onset
ICD-10G30.8
Other Alzheimer's disease
ICD-10G30.9
Alzheimer's disease, unspecified
ICD-9331.0
Alzheimer's disease
A Study of Remternetug Versus Placebo in Early Alzheimer's Disease Participants at Risk for Cognitive and Functional Decline
-
Trial Applicant
ELI LILLY AND COMPANY(TAIWAN), INC.
-
Sponsor
台灣禮來股份有限公司
-
Trial scale
Multi-Regional Multi-Center
-
Update
2026/04/10
Investigators and Locations
Co-Principal Investigator
- Kuan-Fei Chen 無
- Ching-Hua Lu Lu 無
- 程康倫 無
- Yi-Ting Hsu 無
- Yi-Chien Yang 無
- 林欽揚 無
- Hui-Chun Huang 無
The Actual Total Number of Participants Enrolled
0 Recruiting
The Actual Total Number of Participants Enrolled
0 Recruiting
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- 林詠萱 無
- Chun-Yu Chen 無
- 蔡孟儒 無
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- YAO-TUNG LEE 無
- Shu-Ping Chao 無
- Yi-Chun Kuan 無
- YUEH-HSUN LU 無
- Li-Kai Huang 無
- 陳彥廷 無
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- Pin-Kuei Fu 無
- 劉柏伸 無
- 陳虹潔 無
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- 莊宜芳 無
- YEN-HSIANG HUANG 無
- 賴資賢 無
- 甄瑞興 無
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- CHIUNG-MEI CHEN 無
- 張國軒 無
The Actual Total Number of Participants Enrolled
0 Recruiting
The Actual Total Number of Participants Enrolled
0 Recruiting
The Actual Total Number of Participants Enrolled
0 Recruiting
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
The Actual Total Number of Participants Enrolled
0 Recruiting
Condition/Disease
Objectives
Test Drug
Active Ingredient
Dosage Form
Dosage
Endpoints
Measurement Description: Measured up to the time of clinically significant deterioration using the CDR. The CDR is a clinician-rated scale that provides an overall assessment of the stage and extent of impairment in the early stages of Alzheimer's disease (AD) in participants.
Time Range: From the baseline period to the time of the event, up to week 255.
Inclution Criteria
Have a phosphorylated tau (P-tau) result consistent with the presence of amyloid pathology.
Have a reliable study partner and backup study partner familiar with overall function and behavior, such as day-to-day activities and cognitive abilities.
Have adequate literacy, vision, and hearing for neuropsychological testing at screening.
Have a Mini Mental Status Exam (MMSE) score consistent with no to minimal cognitive impairment.
Have a Functional Activities Questionnaire (FAQ) score consistent with no to minimal functional impairment.
If currently receiving medications as symptomatic treatment for AD, dose has been stable for at least 30 days before screening.
Exclusion Criteria
Have dementia or significant other neurological disease that can affect cognition.
Have current serious or unstable illnesses that in the investigator's opinion, could interfere with the analyses of the study.
Have a history of cancer that, in the investigator's opinion, has a high risk of recurrence.
Have a history of clinically significant multiple or severe drug allergies, or hypersensitivity reactions.
Have a clinically important laboratory test result or other abnormality as determined by investigator, prior to randomization, that could be detrimental to the participant or could compromise the study.
Have any contraindications for magnetic resonance imaging (MRI).
Have a centrally read MRI that does not meets study entry criteria.
The Estimated Number of Participants
-
Taiwan
67 participants
-
Global
1400 participants
